Genetically modified bacillus subtilis strain and use as a live delivery and production system
US-2024390433-A1 · Nov 28, 2024 · US
Process for the therapeutic management of diarrhea predominant irritable bowel syndrome using Bacillus coagulans SBC-37-01, MTCC 5856
US9579352B2 · US · B2
| Field | Value |
|---|---|
| Publication number | US-9579352-B2 |
| Application number | US-201414536701-A |
| Country | US |
| Kind code | B2 |
| Filing date | Nov 10, 2014 |
| Priority date | Nov 10, 2014 |
| Publication date | Feb 28, 2017 |
| Grant date | Feb 28, 2017 |
How to read this patent
A practical reading order for non-experts. Skip the full description unless you need deep technical detail.
- Title
What the patent document calls the invention.
- Abstract
A short plain-language summary of the technical disclosure.
- Assignees and inventors
Who owns or filed the patent and who is credited as inventor.
- Key dates
Filing, priority, publication, and grant dates set the timeline.
- First independent claim
The legal scope of protection — read this for what is actually claimed.
- CPC / IPC classifications
Technology tags used to group this patent with similar filings.
- Citations and related patents
Prior art links and similar publications in this corpus.
Abstract
Official abstract text for this publication.
The present invention discloses a process for the therapeutic management of diarrhea predominant irritable bowel syndrome in humans comprising the oral administration of Bacillus coagulans SBC37-01, MTCC 5856 (containing not less than 2 billion spores) along with standard treatment of care in a specific manner.
First claim
Opening claim text (preview).
We claim: 1. A process for the therapeutic management of symptoms associated with diarrhea predominant irritable bowel syndrome in a human subject newly diagnosed with mild to moderate irritable bowel syndrome or previously untreated human subject with mild to moderate irritable bowel syndrome, said process comprising orally administering to said human subject Bacillus Coagulans SBC37-01, deposited under the accession number MTCC 5856 formulation, as a dietary supplement, the formulation containing not less than 2 billion spores at least 30 minutes before a meal, in the morning for a period of 90 days along with standard treatment of care once a day in a manner that a time gap of 4 hours is maintained between the administration of said dietary supplement and the standard treatment of care, wherein said administering enhances the assessed therapeutic efficacy of the standard treatment of care by ameliorating symptoms associated with the irritable bowel syndrome (IBS) in said subject. 2. The process according to claim 1 wherein said standard treatment of care comprising orally administering a combination of 30 mg of Domperidone and 40 mg of Esomeprazole together with 400 mg of Metronidazole once a day. 3. The process according to claim 1 wherein the symptoms associated with irritable bowel syndrome (IBS) are abdominal pain, bloating or visible distension of abdomen, constipation and loose stools.
Assignees
Inventors
Classifications
- A61K35/742Primary
Spore-forming bacteria, e.g. Bacillus coagulans, Bacillus subtilis, clostridium or Lactobacillus sporogenes · CPC title
Probiotics · CPC title
Patent family
Related publications grouped by family.
External sources
Frequently asked questions
Answers are generated from the same data shown on this page.
- What does patent US9579352B2 cover?
- The present invention discloses a process for the therapeutic management of diarrhea predominant irritable bowel syndrome in humans comprising the oral administration of Bacillus coagulans SBC37-01, MTCC 5856 (containing not less than 2 billion spores) along with standard treatment of care in a specific manner.
- Who is the assignee on this patent?
- Majeed Muhammed, Nagabhushanam Kalyanam, Sankaran Natarajan, and 4 more
- What technology area does this patent fall under?
- Primary CPC classification A61K35/742. Mapped technology areas include Human Necessities.
- When was this patent published?
- Publication date Tue Feb 28 2017 00:00:00 GMT+0000 (Coordinated Universal Time) (B2). Legal status and post-grant events are not shown on this page.
- What related patents are in patentsdb?
- We list 8 related publications on this page (citations in our corpus or others sharing the same primary CPC).